PCV109 COST EFFECTIVENESS OF STATIN THERAPY IN SOUTH KOREA  by Bae, EY et al.
Paris Abstracts A333
PCV107
ECONOMIC EVALUATION OF EZETIMIBE COMBINED WITH 
SIMVASTATIN FOR TREATMENT OF PRIMARY 
HYPERCHOLESTEROLAEMIA
Van Nooten F1, Davies GM2, Jukema JW3, Liem AH4, Hu XH5
1United BioSource Corporation, London, UK, 2Merck and Co, Blue Bell, PA, USA, 3Leiden 
University Medical Center, Leiden, The Netherlands, 4Oosterscheldeziekenhuizen, Goes, The 
Netherlands, 5Merck & Co., Inc, West Point, PA, USA
INTRODUCTION: Coronary heart disease (CHD) is a leading cause of death in the 
Western world. Hypercholesterolemia is an important risk factor for CHD. Ezetimibe, 
a cholesterol absorption inhibitor, can be used in combination with statins to improve 
cholesterol levels. OBJECTIVES: The aim was to assess cost-effectiveness of ezetimibe 
combined with simvastatin compared to atorvastatin or simvastatin monotherapy for 
second line treatment of primary hypercholesterolaemia in the Dutch population. 
METHODS: A published Markov model (Cook et al 2004) was adapted to evaluate 
two lipid treatment scenarios in The Netherlands. Baseline patient data from the Dutch 
EASEGO study were used. The ﬁrst scenario was based on this study: patients not 
reaching low-density-lipoprotein cholesterol (LDL-C) goal on atorvastatin 10 mg 
(A10) or simvastatin 20 mg (S20) were included. These patients were modeled using 
a doubled dose, or addition of ezetimibe 10 mg to generic simvastatin (eze10/sim20). 
The second scenario was based on Dutch guidelines. All patients were not meeting 
their LDL-C goal on simvastatin 40 mg (S40) and were switched to atorvastatin 
40 mg (A40), or ezetimibe 10 mg was added to generic simvastatin (eze10/sim40). 
Key effectiveness measure was change in ratio of total cholesterol to high-density-
lipoprotein cholesterol. Model parameters were derived from published literature 
and guidelines. One-way sensitivity analyses were performed for key model parame-
ters. RESULTS: Based on EASEGO the incremental cost-effectiveness ratio for eze10/
sim20 was a3,497 per quality-adjusted life year (QALY) compared to A20 and 
a26,417/QALY compared to S40. Based on Dutch guidelines, eze10/sim40 was domi-
nant, and can be seen to be cost-saving compared with A40 (a3,675/QALY). These 
results were not very sensitive to changes in input parameters. CONCLUSIONS: Eze/
sim can be considered a cost-effective treatment (EASEGO versus A20 or S40) and in 
light of the Dutch guidelines (versus A40) even cost-saving. The addition of ezetimibe 
to simvastatin is a valuable second line treatment option.
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COST EFFECTIVENESS OF MPLANTABLE LOOP RECORDERS (ILRS) FOR 
UNEXPLAINED SYNCOPE DIAGNOSTICS IN FRANCE
Debroucker F, Graciet A
Medtronic France, Boulogne Billancourt Cedex, France
OBJECTIVES: Unexplained Syncope patients have 1.6 times the mortality risk of 
the average population. The “Eastbourne Syncope Assessment Study” (EaSyAS; 
Farwell 2004) is an RCT which demonstrated a signiﬁcantly higher diagnostic 
yield in unexplained syncope patients using ILRs (Reveal, Medtronic) (34/101 
Patients diagnosed (33.7%) versus a conventional diagnostic strategy (4/97 Patients 
diagnosed (4.1%); p  0.001) after a mean follow-up period of 9 months. The study           
also included detailed health care utilisation analysis, ultimately demonstrating 
a reduced cost-per-correct-diagnosis under the UK setting and signiﬁcant reductions 
in the overall volume of diagnostic tests. We sought to explore potential cost implica-
tions of ILR use in this patient population, from the perspective of the French Social 
Security. METHODS: We used EaSyAS to assess the type and volume of diagnostic 
tests used. Direct medical costs were derived from the 2008 CCAM Procedure Tariff 
and DRG Tariff. Reveal selling price was used to assess ILR cost. RESULTS: The 
cost of a successfully diagnosing an unexplained syncope patient with Reveal is 
4.7 times lower than the equivalent cost using a conventional strategy. This allows 
for a moderate ICER equal to a2535.60 on a cost-per-diagnosis basis.Two univariate 
sensitivity analysis on the device cost and the procedures cost showed little impact 
on the ICER. CONCLUSIONS: Although this analysis was based on UK short term 
data, its results are consistent with analyses performed in other developed countries. 
The analysis demonstrated an ICER below a4,000 on a cost-per-diagnosis basis. This 
could mean that ILR use in France has the potential for signiﬁcant cost-savings in this 
patient population. The upcoming FREnch Syncope study on Holter monitoring 
(FRESH) should allow for a more precise assessment of cost-savings achieved with 
ILRs in France.
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OBJECTIVES: The Korean government announced in December 2006 that only 
medications with good value for money, based on cost-effectiveness analysis, will be 
reimbursed in the Korean National Health Insurance program. As a pilot program, 
Health Insurance Review and Assessment Service (HIRA) conducted cost-effectiveness 
analysis of already listed medications, triptans and statins, in 2007. The purpose of 
this study was to examine cost-effectiveness of statin medications in Korea. 
METHODS: We conducted systematic review(s) to evaluate the clinical signiﬁcance 
of 7 statin medications available in Korea: Atorvastatin, Lovastatin, Fluvastatin, 
Pitavastatin, Pravastatin, Rosuvastatin, and Simvastatin. Meta-analyses were con-
ducted to summarize comparative effectiveness of statin medications. Costs of relevant 
diseases (Angina, MI, stroke) were estimated based on the claims data. Lifetime cost 
and health outcomes associated with statin treatment were projected based on a 
Markov model. A societal perspective was taken. Target population was 55-year-old 
Korean patients whose cholesterol level is elevated, with (secondary prevention) and 
without (primary prevention) previous history of CHD or CVD. RESULTS: The result 
of the Meta-analysis suggests that statin therapy is associated with reduced relative 
risk of all cause mortality, CVD mortality, CHD mortality, MI, and angina, but not 
stroke mortality at statistically signiﬁcant level. However, currently available evidence 
was not enough to suggest whether the clinical effectiveness of Atorvastatin, Fluvas-
tain, Lovastatin, Pravastatin, and Simvastatin was statistically signiﬁcantly superior 
than the rest of the statin. No published study was found regarding Pitavastain on 
CHD/CVD outcomes; Rosuvastatin study on CHD/CVD outcomes was only con-
ducted among limited population. In Primary prevention, the incremental cost-
 effectiveness ratios (ICERs) were KRW /LYG and KRW/QALY; in secondary 
prevention, the ICER decreased to KRW /LYG and KRW/QALY. The results of the 
sensitivity analyses were consistent with those of base case. CONCLUSIONS: Under 
current price, Statin therapy are less cost-effective when used as a primary prevention, 
compared with secondary prevention.
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OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) comparing 35 days of 
prophylaxis (extended enoxaparin) with short term prophylaxis (12 days enoxaparin) 
for thromboprophylaxis of venous thromboembolism (VTE) in patients undergoing 
elective total hip replacement (THR) surgery at high risk for VTE. The analysis was 
for a lifetime horizon from a Canadian payer perspective. METHODS: A Markov 
model was developed to estimate incremental cost per life year gained and quality-
adjusted life year (QALY) gained. Clinical outcomes considered in the model included 
symptomatic deep-vein thrombosis (DVT), pulmonary embolism (PE), post-throm-
botic syndrome (PTS), and major bleeding associated with thromboprophylaxis. 
Treatment-speciﬁc event rates for DVT, PE and major bleeding were derived as pooled 
estimates from 3 pivotal clinical trials of extended enoxaparin versus short-term 
enoxaparin. Ontario resource utilization and unit costs derived from published litera-
ture were applied to trial-based drug treatment and events to estimate the costs of 
drug acquisition and administration, and diagnosing and managing DVT, PE, PTS 
and major bleeding. Utility weights used in the calculation of QALYs were also derived 
from the literature. RESULTS: Compared with short-term enoxaparin extended 
enoxaparin resulted in 39.6 fewer VTE events per 1,000 patients and a gain of 
approximately 0.01 life years and QALYs per patient. Total costs were higher for 
extended enoxaparin, resulting in an incremental cost of CAD$22,675 per life year 
gained and $26,254 per QALY gained (discounted at 5% per year). The results were 
most sensitive to assumptions regarding the percentage of patients requiring home 
nursing to administer enoxaparin. CONCLUSIONS: In patients undergoing elective 
THR surgery, extended thromboprophylaxis with enoxaparin reduces the risk of VTE 
and provides favourable cost-effectiveness ratios compared with short-term thrombo-
prophylaxis only with enoxaparin. The analysis demonstrates that extended throm-
boprophylaxis with enoxaparin in patients undergoing THR surgery represents a 
cost-effective use of resources.
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OBJECTIVES: To evaluate from the patient’s perspective, the ICERs (Incremental 
Cost-Effectiveness Ratio) of using aspirin as UK guideline based CVD (Cardiovascular 
Disease) primary prevention in middle-aged men compared to no pharmacotherapy. 
METHODS: A Markov-model was used to investigate the cost-effectiveness of low-         
dose aspirin in a hypothetical population of initially healthy men (55 years old) with 
15% CVD risk, up to 100 years of age or death. For the base-case scenario, it was 
assumed that all would take OTC (Over The Counter) aspirin. Those experiencing a 
CVD event would be switched to POM, (Prescription Only Medicine) aspirin plus 
statin. After a bleeding event, aspirin would be permanently discontinued. If the event 
was GI-bleeding, aspirin was replaced by POM clopidogrel. All were assumed to pay 
prescription charges until aged 59. The main effect outcomes are QALYs (Quality-
Adjusted Life Years) and LYG (Life-Years Gained). The main costs are prescription 
charges, purchase of OTC aspirin, income loss and travel costs. Published studies on   
the efﬁcacy of aspirin and clopidogrel for primary prevention, their side-effects and 
the NICE technology assessment report “Statins for the Prevention of Coronary 
Events” published in 2005 were used as sources for transition probabilities, relative 
risks and utility values. Cost data were sourced from the NHS and “HM Revenue & 
Customs” databases, and average retail UK prices. RESULTS: The estimated incre-
mental cost-effectiveness is: cost-saving of £200.44 (95%CI: £142.10 to £264.48), 
gain of 0.044 (95%CI: 0.005–0.075) QALYs and loss of 0.017(95%CI: 0.069 to 
0.025) LYG. In univariate analyses, baseline CVD risk, income loss and aspirin effect 
on transitions from healthy to haemorrhagic stroke, cerebro-vascular death and GI-
bleeding had the greatest impact on the results. CONCLUSIONS: Low-dose aspirin 
